Cargando…
The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis
BACKGROUND: Antipsychotic medications, particularly second-generation antipsychotics, are increasingly being used to alleviate the symptoms of schizophrenia and other severe mental disorders in the pediatric population. While evidence-based approaches examining efficacy and safety outcomes have been...
Autores principales: | Druyts, Eric, Eapen, Shawn, Wu, Ping, Thorlund, Kristian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199775/ https://www.ncbi.nlm.nih.gov/pubmed/25312992 http://dx.doi.org/10.1186/2046-4053-3-116 |
Ejemplares similares
-
Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review
por: Druyts, Eric, et al.
Publicado: (2016) -
Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis
por: Balijepalli, Chakrapani, et al.
Publicado: (2018) -
Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis
por: Thorlund, Kristian, et al.
Publicado: (2014) -
Antipsychotic medication for women with schizophrenia spectrum disorders
por: Brand, Bodyl A., et al.
Publicado: (2022) -
Antipsychotic medication for women with schizophrenia spectrum disorders – CORRIGENDUM
por: Brand, Bodyl A., et al.
Publicado: (2023)